Schwab Charles Investment Management Inc. lifted its holdings in shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) by 36.9% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,850 shares of the company’s stock after buying an additional 1,306 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Taro Pharmaceutical Industries were worth $544,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Bessemer Group Inc. boosted its stake in Taro Pharmaceutical Industries by 138.6% during the 2nd quarter. Bessemer Group Inc. now owns 2,083 shares of the company’s stock valued at $234,000 after purchasing an additional 1,210 shares during the period. Bank of Montreal Can boosted its stake in Taro Pharmaceutical Industries by 7.5% during the 2nd quarter. Bank of Montreal Can now owns 2,128 shares of the company’s stock valued at $238,000 after purchasing an additional 149 shares during the period. Russell Investments Group Ltd. boosted its stake in Taro Pharmaceutical Industries by 7.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,257 shares of the company’s stock valued at $253,000 after purchasing an additional 156 shares during the period. US Bancorp DE boosted its stake in Taro Pharmaceutical Industries by 49.4% during the 2nd quarter. US Bancorp DE now owns 2,983 shares of the company’s stock valued at $334,000 after purchasing an additional 986 shares during the period. Finally, Eagle Global Advisors LLC acquired a new position in Taro Pharmaceutical Industries during the 2nd quarter valued at about $616,000. 14.20% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Schwab Charles Investment Management Inc. Acquires 1,306 Shares of Taro Pharmaceutical Industries Ltd. (TARO)” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/schwab-charles-investment-management-inc-acquires-1306-shares-of-taro-pharmaceutical-industries-ltd-taro/1677166.html.

Taro Pharmaceutical Industries Ltd. (NYSE TARO) opened at $114.50 on Friday. The company has a market cap of $4,565.00, a PE ratio of 11.48 and a beta of 0.65.

TARO has been the subject of a number of analyst reports. TheStreet raised shares of Taro Pharmaceutical Industries from a “c” rating to a “b-” rating in a research note on Thursday, July 20th. BidaskClub raised shares of Taro Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Thursday, September 28th.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Institutional Ownership by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.